DCPH - Deciphera Pharmaceuticals Inc Stock Price, Fair Value and News

25.46USD+0.01 (+0.04%)Delayed

Market Summary

USD25.46+0.01

Delayed

0.04%

DCPH Alerts

Big jump in Revenue (Y/Y)

Big jump in Earnings (Y/Y)
Losses in recent quarter

DCPH Stock Price

View Fullscreen

DCPH RSI Chart

DCPH Valuation

Market Cap

2.2B

Price/Earnings (Trailing)

-17.5

Price/Sales (Trailing)

12.59

EV/EBITDA

-10.96

Price/Free Cashflow

-14.45

DCPH Price/Sales (Trailing)

DCPH Profitability

EBT Margin

-111.21%

Return on Equity

-39.8%

Return on Assets

-29.88%

Free Cashflow Yield

-6.92%

DCPH Fundamentals

DCPH Revenue

Revenue (TTM)

174.9M

Rev. Growth (Yr)

34.55%

Rev. Growth (Qtr)

-6.82%

DCPH Earnings

Earnings (TTM)

-125.8M

Earnings Growth (Yr)

74.79%

Earnings Growth (Qtr)

-358.37%

Breaking Down DCPH Revenue

Last 7 days

0.4%

Last 30 days

73.0%

Last 90 days

62.5%

Trailing 12 Months

83.3%

How does DCPH drawdown profile look like?

DCPH Financial Health

Current Ratio

4.19

DCPH Investor Care

Shares Dilution (1Y)

10.13%

Diluted EPS (TTM)

-2.21

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	174.9M	0	0	0
2023	138.3M	144.1M	151.4M	163.4M
2022	100.2M	109.1M	121.9M	134.0M
2021	67.2M	83.7M	91.4M	96.1M
2020	0	30.7M	36.4M	42.1M
2019	0	0	0	25.0M

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Deciphera Pharmaceuticals Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 22, 2024	brightstar associates llc	acquired	481	0.01	48,136	-
Feb 16, 2024	kelly thomas patrick	sold	-47,009	15.6177	-3,010	chief financial officer
Feb 16, 2024	pitman jama	sold	-35,405	15.6176	-2,267	svp, chief development officer
Feb 16, 2024	sherman matthew l	sold	-40,840	15.6177	-2,615	evp & chief medical officer
Feb 16, 2024	martin daniel c.	sold	-35,405	15.6176	-2,267	chief commercial officer
Feb 15, 2024	sherman matthew l	acquired	-	-	17,275	evp & chief medical officer
Feb 15, 2024	kelly thomas patrick	acquired	-	-	17,275	chief financial officer
Feb 15, 2024	martin daniel c.	acquired	-	-	9,725	chief commercial officer
Feb 15, 2024	pitman jama	acquired	-	-	19,725	svp, chief development officer
Feb 15, 2024	dhanak dashyant	acquired	-	-	17,275	evp & chief scientific officer

Which funds bought or sold DCPH recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	reduced	-6.39	-56,744	594,327	-%
May 16, 2024	COMERICA BANK	unchanged	-	-115	4,546	-%
May 16, 2024	JANE STREET GROUP, LLC	reduced	-83.86	-1,244,600	232,474	-%
May 15, 2024	Frazier Life Sciences Management, L.P.	added	42.48	6,418,680	22,900,300	0.97%
May 15, 2024	Engineers Gate Manager LP	new	-	367,720	367,720	0.01%
May 15, 2024	QUADRANT CAPITAL GROUP LLC	unchanged	-	-786	30,910	-%
May 15, 2024	JANUS HENDERSON GROUP PLC	added	0.01	-10,978	417,195	-%
May 15, 2024	Woodline Partners LP	sold off	-100	-6,391,340	-	-%
May 15, 2024	Schonfeld Strategic Advisors LLC	added	28.53	1,142,760	5,651,270	0.04%
May 15, 2024	Cubist Systematic Strategies, LLC	reduced	-9.88	-543,871	3,946,480	0.02%

Are Funds Buying or Selling DCPH?

Are funds buying DCPH calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own DCPH

No. of Funds

Unveiling Deciphera Pharmaceuticals Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	braidwell lp	2.92%	2,385,623	SC 13G/A
Feb 14, 2024	armistice capital, llc	6.49%	5,200,000	SC 13G/A
Feb 14, 2024	redmile group, llc	9.9%	8,359,768	SC 13G/A
Feb 13, 2024	vanguard group inc	5.49%	4,401,636	SC 13G/A
Feb 12, 2024	flynn james e	7.19%	5,788,024	SC 13G/A
Feb 09, 2024	brightstar associates llc	28.2%	23,059,708	SC 13G/A
Feb 06, 2024	goldman sachs group inc	2.5%	2,007,447	SC 13G/A
Jan 26, 2024	blackrock inc.	7.5%	5,976,266	SC 13G/A
Jan 23, 2024	state street corp	3.08%	2,470,813	SC 13G/A
Mar 22, 2023	flynn james e	6.09%	4,627,310	SC 13G

Recent SEC filings of Deciphera Pharmaceuticals Inc

View All Filings

Date Filed	Form Type	Document
May 13, 2024	SC 14D9	SC 14D9
May 13, 2024	SC TO-T	SC TO-T
May 10, 2024	10-Q	Quarterly Report
May 06, 2024	SC TO-C	SC TO-C
Apr 30, 2024	SC TO-C	SC TO-C
Apr 30, 2024	SC14D9C	SC14D9C
Apr 29, 2024	8-K	Current Report
Apr 29, 2024	SC14D9C	SC14D9C
Apr 29, 2024	SC14D9C	SC14D9C
Apr 25, 2024	ARS	ARS

Peers (Alternatives to Deciphera Pharmaceuticals Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
JNJ	372.2B	85.6B	6.82%	-1.69%	9.67	4.35	5.68%	202.39%
MRK	332.3B	61.4B	4.65%	15.09%	144.1	5.41	6.11%	-82.30%
AMGN	167.7B	29.5B	18.35%	39.38%	44.55	5.68	12.76%	-52.47%
PFE	162.3B	57.8B	12.71%	-21.46%	129.52	2.81	76.51%	-86.81%
GILD	84.4B	27.4B	1.23%	-13.37%	174.21	3.07	1.51%	-91.32%
TEVA	18.4B	16.0B	23.52%	97.09%	-37.29	1.15	7.23%	71.10%
MID-CAP
ALKS	4.1B	1.7B	0.67%	-19.91%	9.41	2.37	54.01%	364.56%
PRGO	4.1B	4.6B	-0.70%	-10.77%	-528.11	0.89	-0.06%	94.55%
BHC	2.5B	9.0B	-21.94%	-21.03%	-5.45	0.28	10.01%	-27.45%
AMPH	2.1B	676.2M	8.56%	-0.82%	13.75	3.14	30.38%	66.04%
SMALL-CAP
TLRY	1.5B	743.2M	15.12%	-18.85%	-4.35	2.06	24.65%	80.36%
TXMD	25.8M	1.3M	18.52%	-47.17%	-3.49	19.84	-98.14%	-104.71%
ACRX	18.4M	89.6M	6.93%	25.60%	-1.29	0.19	287.27%	-129.41%
AGRX	2.5M	21.5M	2.70%	-90.89%	-0.32	0.12	66.16%	61.83%
ACOR	633.5K	115.7M	-50.00%	-97.38%	0	0.01	-2.22%	-352.48%

Deciphera Pharmaceuticals Inc News

Latest updates

Deciphera Pharmaceuticals Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Millions)
Income Statement (Quarterly)																			(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2019Q4	2019Q3	2019Q2
Revenue	-6.8%	44,999,000	48,294,000	43,313,000	38,304,000	33,445,000	36,345,000	35,974,000	32,494,000	29,223,000	24,199,000	23,220,000	23,573,000	25,156,000	19,486,000	15,449,000	7,090,000	13,060,000	19,030,000	25,000,000
Costs and Expenses	-5.7%	93,846,000	99,532,000	97,001,000	91,079,000	86,702,000	83,506,000	80,855,000	76,282,000	76,115,000	112,600,000	102,888,000	94,087,000	86,650,000	82,485,000	79,446,000	76,022,000	70,373,000	58,353,000	47,975,000
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	70,373,000	58,353,000	47,975,000
S&GA Expenses	-13.3%	33,924,000	39,148,000	33,252,000	32,610,000	31,449,000	32,195,000	30,026,000	29,625,000	28,321,000	37,151,000	35,527,000	32,828,000	30,747,000	30,070,000	30,143,000	29,933,000	23,737,000	17,979,000	13,164,000
R&D Expenses	-1.3%	57,834,000	58,599,000	62,463,000	58,296,000	54,765,000	48,066,000	47,485,000	44,858,000	47,412,000	74,931,000	66,444,000	59,984,000	55,681,000	52,288,000	49,213,000	46,081,000	46,636,000	40,374,000	34,811,000
EBITDA Margin	6.5%	-1.10	-1.18	-1.16	-1.22	-1.27	-1.31	-2.44	-2.72	-2.96	-3.09	-2.88	-3.15	-	-	-	-	-	-	-
Interest Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	12,000	17,000	25,000
EBT Margin	6.6%	-1.11	-1.19	-1.18	-1.24	-1.29	-1.33	-2.46	-2.75	-2.99	-3.12	-2.91	-3.19	-	-	-	-	-	-	-
Net Income	-358.4%	-45,100,000	17,455,500	-49,581,000	-48,562,000	-178,900,000	-45,935,000	-43,043,000	-43,061,000	-46,892,000	-88,395,000	-79,838,000	-70,433,000	-61,298,000	-62,740,000	-63,701,000	-67,241,000	-67,216,000	-56,196,000	-21,460,000
Net Income Margin	54.7%	-0.72	-1.59	-2.13	-2.20	-2.25	-1.33	-1.82	-2.37	-2.85	-3.12	-3.00	-3.09	-	-	-	-	-	-	-
Free Cashflow	-89.6%	-54,731,000	-28,872,000	-29,869,000	-38,919,000	-49,815,000	-35,139,000	-21,401,000	-45,811,000	-51,352,000	-66,067,000	-56,009,000	-52,399,000	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-11.1%	421	474	498	510	549	454	476	507	385	429	483	541	595	642	660	686	733	622	650	260	270
Current Assets	-8.2%	350	381	418	405	476	393	421	449	320	339	385	437	547	584	571	633	703	593	642	256	266
Cash Equivalents	9.2%	91.00	84.00	108	81.00	115	65.00	83.00	110	95.00	87.00	53.00	91.00	202	136	111	155	230	120	174	57.00	82.00
Inventory	22.7%	26.00	21.00	27.00	25.00	26.00	21.00	19.00	21.00	20.00	14.00	7.00	8.00	7.00	6.00	5.00	1.00	-	-	-	-	-
Net PPE	-4.9%	5.00	5.00	6.00	6.00	7.00	7.00	7.00	7.00	8.00	9.00	11.00	10.00	10.00	10.00	10.00	10.00	7.00	6.00	5.00	2.00	2.00
Liabilities	-14.5%	105	123	116	105	109	112	102	102	114	125	103	94.00	92.00	99.00	91.00	67.00	61.00	76.00	44.00	37.00	30.00
Current Liabilities	-16.8%	83.00	100	93.00	81.00	84.00	86.00	75.00	75.00	87.00	97.00	76.00	66.00	64.00	70.00	61.00	51.00	45.00	60.00	42.00	35.00	28.00
Shareholder's Equity	-9.9%	316	351	382	404	440	342	374	405	272	305	380	447	503	544	569	620	672	546	606	223	240
Retained Earnings	-5.2%	-1,473	-1,400	-1,400	-1,300	-1,282	-1,233	-1,200	-1,144	-1,101	-1,054	-966	-886	-815	-754	-691	-628	-560	-487	-420	-364	-343
Additional Paid-In Capital	0.6%	1,789	1,778	1,763	1,736	1,722	1,575	1,563	1,550	1,373	1,359	1,346	1,332	1,318	1,298	1,260	1,247	1,232	1,034	1,026	587	583
Shares Outstanding	2.1%	82.00	81.00	80.00	79.00	79.00	68.00	73.00	68.00	59.00	58.00	58.00	58.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	777	-	-	-	636	-	-	-	1,504	-	-	-	2,347	-	-	-	446	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-89.5%	-54,585	-28,809	-29,807	-38,626	-49,455	-35,158	-20,828	-45,524	-51,352	-67,176	-53,999	-51,967	-67,682	-49,128	-49,341	-60,844	-80,370	-55,833	-23,191	-37,266	-33,006
Share Based Compensation	-27.7%	10,174	14,073	11,160	12,856	12,514	12,313	12,373	12,988	14,268	10,794	11,794	12,371	11,119	9,706	9,828	10,609	6,994	5,345	4,729	4,107	6,229
Cashflow From Investing	2748.2%	62,631	2,199	41,403	4,361	-35,414	16,304	-6,071	-104,194	59,652	98,952	14,441	-60,453	123,908	46,079	1,821	-17,751	-1,690	1,680	-294,810	12,256	-179,648
Cashflow From Financing	-41.3%	522	890	15,590	838	134,686	478	209	164,224	83.00	1,978	1,706	1,682	9,524	27,792	3,228	4,389	191,392	761	434,476	19.00	1,118

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

DCPH Income Statement

2024-03-31

Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Total revenues	$ 44,999	$ 33,445
Cost and operating expenses:
Cost of sales	2,088	488
Research and development	57,834	54,765
Selling, general, and administrative	33,924	31,449
Total cost and operating expenses	93,846	86,702
Loss from operations	(48,847)	(53,257)
Other income:
Interest and other income, net	3,764	3,648
Total other income, net	3,764	3,648
Net loss	$ (45,083)	$ (49,609)
Net loss per share—diluted (in dollars per share)	$ (0.52)	$ (0.60)
Net loss per share—basic (in dollars per share)	$ (0.52)	$ (0.60)
Weighted average common shares outstanding—diluted (in shares)	87,388,106	82,676,624
Weighted average common shares outstanding—basic (in shares)	87,388,106	82,676,624
Comprehensive loss:
Net loss	$ (45,083)	$ (49,609)
Other comprehensive income (loss):
Unrealized gains (losses) on marketable securities	(206)	709
Currency translation adjustment	(273)	93
Total other comprehensive income (loss)	(479)	802
Total comprehensive loss	(45,562)	(48,807)
Share-based compensation expense	10,174	12,514
Product revenues, net
Total revenues	42,550	33,222
Collaboration revenues
Total revenues	$ 2,449	$ 223

DCPH Balance Sheet

2024-03-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 91,228	$ 83,507
Short-term marketable securities	181,299	222,709
Accounts receivable, net	32,684	31,952
Inventory	21,098	21,210
Prepaid expenses and other current assets	23,628	21,718
Total current assets	349,937	381,096
Long-term marketable securities	26,778	46,699
Other long-term assets and long-term investments—restricted	8,133	8,277
Property and equipment, net	5,155	5,421
Operating lease assets	30,925	32,073
Total assets	420,928	473,566
Current liabilities:
Accounts payable	19,459	26,476
Accrued expenses and other current liabilities	60,396	70,295
Operating lease liabilities	3,574	3,504
Total current liabilities	83,429	100,275
Operating lease liabilities, net of current portion	21,449	22,375
Total liabilities	104,878	122,650
Commitments and contingencies (Note 7)
Stockholders' equity:
Preferred stock, $0.01 par value per share; 5,000,000 shares authorized; no shares issued or outstanding	0	0
Common stock, $0.01 par value per share; 125,000,000 shares authorized; 82,158,670 shares and 80,503,338 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively	821	805
Additional paid-in capital	1,788,519	1,777,839
Accumulated other comprehensive income (loss)	98	577
Accumulated deficit	(1,473,388)	(1,428,305)
Total stockholders' equity	316,050	350,916
Total liabilities and stockholders' equity	$ 420,928	$ 473,566

About Deciphera Pharmaceuticals Inc

Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing vimseltinib, an orally administered, potent, and highly selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) for the treatment of tenosynovial giant cell tumor (TGCT); and DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.

CEO	Mr. Steven L. Hoerter
WEBSITE	deciphera.com
INDUSTRY	Pharmaceuticals
EMPLOYEES	300

Deciphera Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for Deciphera Pharmaceuticals Inc? What does DCPH stand for in stocks?

DCPH is the stock ticker symbol of Deciphera Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Deciphera Pharmaceuticals Inc (DCPH)?

As of Fri May 17 2024, market cap of Deciphera Pharmaceuticals Inc is 2.2 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of DCPH stock?

You can check DCPH's fair value in chart for subscribers.

What is the fair value of DCPH stock?

You can check DCPH's fair value in chart for subscribers. The fair value of Deciphera Pharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Deciphera Pharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for DCPH so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Deciphera Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether DCPH is over valued or under valued. Whether Deciphera Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Deciphera Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for DCPH.

What is Deciphera Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, DCPH's PE ratio (Price to Earnings) is -17.5 and Price to Sales (PS) ratio is 12.59. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. DCPH PE ratio will change depending on the future growth rate expectations of investors.